Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 28;15(11):2171.
doi: 10.3390/v15112171.

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Affiliations

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Danielle E Lyons et al. Viruses. .

Abstract

Despite remarkable progress, a cure for HIV-1 infection remains elusive. Rebound competent latent and transcriptionally active reservoir cells persevere despite antiretroviral therapy and rekindle infection due to inefficient proviral silencing. We propose a novel "block-lock-stop" approach, entailing long term durable silencing of viral expression towards an irreversible transcriptionally inactive latent provirus to achieve long term antiretroviral free control of the virus. A graded transformation of remnant HIV-1 in PLWH from persistent into silent to permanently defective proviruses is proposed, emulating and accelerating the natural path that human endogenous retroviruses (HERVs) take over millions of years. This hypothesis was based on research into delineating the mechanisms of HIV-1 latency, lessons from latency reversing agents and advances of Tat inhibitors, as well as expertise in the biology of HERVs. Insights from elite controllers and the availability of advanced genome engineering technologies for the direct excision of remnant virus set the stage for a rapid path to an HIV-1 cure.

Keywords: HERV; HIV-1 cure; latency; transcriptional silencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The block-lock-stop approach is multipronged to drive HIV-1 from reversible latency to deep silencing and permanent inactivation.

Similar articles

Cited by

References

    1. Thomas J., Ruggiero A., Paxton W.A., Pollakis G. Measuring the Success of HIV-1 Cure Strategies. Front. Cell. Infect. Microbiol. 2020;10:134. doi: 10.3389/fcimb.2020.00134. - DOI - PMC - PubMed
    1. Ta T.M., Malik S., Anderson E.M., Jones A.D., Perchik J., Freylikh M., Sardo L., Klase Z.A., Izumi T. Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies. Front. Microbiol. 2022;13:862270. doi: 10.3389/fmicb.2022.862270. - DOI - PMC - PubMed
    1. Oomen P.G.A., Dijkstra S., Hofstra L.M., Nijhuis M.M., Verbon A., Mudrikova T., Wensing A.M.J., Hoepelman A.I.M., Van Welzen B.J. Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study. J. Med. Virol. 2023;95:e29178. doi: 10.1002/jmv.29178. - DOI - PubMed
    1. Singh K., Natarajan V., Dewar R., Rupert A., Badralmaa Y., Zhai T., Winchester N., Scrimieri F., Smith M., Davis I., et al. Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: Implications for persistent immune activation during antiretroviral therapy. AIDS. 2023;37:2119–2130. doi: 10.1097/QAD.0000000000003667. - DOI - PMC - PubMed
    1. Mavigner M., Delobel P., Cazabat M., Dubois M., L’Faqihi-Olive F.E., Raymond S., Pasquier C., Marchou B., Massip P., Izopet J. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS ONE. 2009;4:e7658. doi: 10.1371/journal.pone.0007658. - DOI - PMC - PubMed